Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II, Multicentre, Open Label Study to Evaluate the Efficacy of the Combination of Lanreotide Autogel 120mg and Temozolomide in Patients With Progressive Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET) G1/G2 - A Pilot-Study
Brief Summary: The purpose of the study is to evaluate the efficacy and tolerability of the combination of Lanreotide Autogel 120 mg and Temozolomide in patients with progressive gastro-entero-pancreatic neuroendocrine tumours (GEP-NET) graded as G1 or G2 (G1/G2). All progressive tumours classified according to Response Evaluation Criteria In Solid Tumours (RECIST, 1.1).


Options:
A: Arm Label: Lanreotide Autogel 120mg & Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Lanreotide Autogel 120 mg, Drug: Temozolomide (TMZ) | Intervention Type: DRUG; Name: Lanreotide Autogel 120 mg; Assigned to Arm(s): Lanreotide Autogel 120mg & Temozolomide | Intervention Type: DRUG; Name: Temozolomide (TMZ); Assigned to Arm(s): Lanreotide Autogel 120mg & Temozolomide
B: Arm Label: BEZ235; Type: EXPERIMENTAL; Interventions: Drug: BEZ235 | Arm Label: Everolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus | Intervention Type: DRUG; Name: BEZ235; Assigned to Arm(s): BEZ235 | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus
C: Arm Label: 177Lu-DOTA-EB-TATE 1; Type: EXPERIMENTAL; Interventions: Drug: 177Lu-DOTA-EB-TATE 1 | Arm Label: 177Lu-DOTA-EB-TATE 2; Type: EXPERIMENTAL; Interventions: Drug: 177Lu-DOTA-EB-TATE 2 | Arm Label: 177Lu-DOTA-EB-TATE 3; Type: EXPERIMENTAL; Interventions: Drug: 177Lu-DOTA-EB-TATE 3 | Arm Label: 177Lu-DOTA-TATE; Type: EXPERIMENTAL; Interventions: Drug: 177Lu-DOTA-TATE | Arm Label: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine); Type: EXPERIMENTAL; Interventions: Drug: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine) | Arm Label: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine); Type: EXPERIMENTAL; Interventions: Drug: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine) | Intervention Type: DRUG; Name: 177Lu-DOTA-EB-TATE 1; Assigned to Arm(s): 177Lu-DOTA-EB-TATE 1 | Intervention Type: DRUG; Name: 177Lu-DOTA-TATE; Assigned to Arm(s): 177Lu-DOTA-TATE | Intervention Type: DRUG; Name: 177Lu-DOTA-EB-TATE 2; Assigned to Arm(s): 177Lu-DOTA-EB-TATE 2 | Intervention Type: DRUG; Name: 177Lu-DOTA-EB-TATE 3; Assigned to Arm(s): 177Lu-DOTA-EB-TATE 3 | Intervention Type: DRUG; Name: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine); Assigned to Arm(s): 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine) | Intervention Type: DRUG; Name: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine); Assigned to Arm(s): 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine)
D: Arm Label: 250 mg Telotristat Etiprate; Type: EXPERIMENTAL; Interventions: Drug: Telotristat etiprate, Drug: Placebo | Arm Label: 500 mg Telotristat Etiprate; Type: EXPERIMENTAL; Interventions: Drug: Telotristat etiprate, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Telotristat etiprate; Assigned to Arm(s): 250 mg Telotristat Etiprate, 500 mg Telotristat Etiprate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 250 mg Telotristat Etiprate, 500 mg Telotristat Etiprate, Placebo

Answer: A